Sfoglia per AUTORE
CUNEO A
Collezione ASL Asti

  

Items : 16

Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group. in Hematological oncology / Hematol Oncol. 2021 Aug;39(3):326-335. doi: 10.1002/hon.2861. Epub 2021 Mar 26.

2021
ASL Asti
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara

Cuneo A; Foà R; Marchetti M; Gentile M; Vignetti M; Mauro FR; Crea E; Marasca R; Laurenti L; Molinari AL; Pietrasanta D; Quaglia FM; Sportoletti P; Paolini R; Varettoni M; Gaidano G; Murru R; Vitagliano O; Coscia M; Farina L; Cibien F; Zamprogna G; Arena V; Visentin A; Reda G; Cavazzini F; Piciocchi A; Montillo M; Rigolin GM; et alii...

OBINUTUZUMAB PLUS CHLORAMBUCIL VERSUS IBRUTINIB IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WITHOUT TP53 DISRUPTIONS. A CAMPUS CLL STUDY in Haematologica

2021
ASL Asti

Visentin A; Pravato S; Mauro FR; Pietrasanta D; Fresa A; Vitale C; Ciolli S; Cassin R; Cibien F; Sportoletti P; Gentile M; Rigolin GM; Quaglia FM; Murru R; Gozzetti A; Molica S; Marchetti M; Scarfò L; Guardalben E; Avitabile A; Reda G; Coscia M; Laurenti L; Pizzolo G; Semenzato G; Foà R; Cuneo A; Trentin L;

Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. in Cancer medicine / Cancer Med. 2020 Nov;9(22):8468-8479. doi: 10.1002/cam4.3470. Epub 2020 Sep 24.

2020
ASL Asti
AOU Città della Salute di Torino
ASL Vercelli
AO Cuneo
AOU Novara

Vignetti M; Foà R; Ghia P; Cimino G; Cavallari M; Cucci R; de la Serna J; Ferrarini I; Medina Perez A; Mauro FR; Coscia M; Di Raimondo F; Farina L; Molica S; Gaidano G; Doubek M; Ilariucci F; Tedeschi A; Marchetti M; Spacek M; Trentin L; Billio A; Ujjani CS; Roeker L; Orlandi EM; Schuster SJ; Shah NN; Sehgal AR; Pu JJ; et alii...

Clinical Characteristics and Outcome of West Nile Virus Infection in Patients with Lymphoid Neoplasms: An Italian Multicentre Study. in HemaSphere / Hemasphere. 2020 Jun 8;4(3):e395. doi: 10.1097/HS9.0000000000000395. eCollection 2020 Jun.

2020
ASL Asti
ASL Vercelli

Trentin L; Semenzato G; Marasca R; Cuneo A; Luppi M; Bassan R; Krampera M; Marinello S; Piazza F; Gherlinzoni F; Riva M; Briani C; Cibien F; Rigolin GM; Paolini R; Sancetta R; Ferrarini I; Marchetti M; Nasillo V; Visentin A;

Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report. in Blood / Blood. 2020 Aug 6;136(6):763-766. doi: 10.1182/blood.2020006854.

2020
ASL Asti
AOU Città della Salute di Torino
ASL Vercelli

Foà R; Marasca R; Laurenti L; Trentin L; Mauro FR; Gattei V; Ibatici A; Rigolin GM; Orsucci L; Pietrasanta D; Re F; Marchetti M; De Paoli L; Varettoni M; Quaglia FM; Reda G; Scarfò L; Cuneo A;

Complex Karyotype Is Associated with A Less Favorable Outcome after Ibrutinib and Rituximab As Front-Line Treatment of Unfit Patients with Chronic Lymphocytic Leukemia (GIMEMA LLC1114) in Haematologica

2020
ASL Asti

Del Giudice I; Rigolin GM; Bardi A; Melandri A; Cavallari M; Raponi S; Ilari C; Cafforio L; Piciocchi A; Arena V; Fabri S; Albano F; Nanni M; Molica S; Reda G; Sportoletti M; Trentin L; Marchetti M; Peragine N; Mariglia P; Vignetti M; Mauro FR; Guarini A; Foà R; Cuneo A;

Worldwide Examination of Patients with CLL Hospitalized for COVID-19 in Blood

2020
ASL Asti
AOU Città della Salute di Torino

Roeker LE; Scarfo L; Chatzikonstantinou T; Abrisqueta P; Eyre TA; Cordoba R; Muntañola Prat A; Villacampa G; Leslie LA; Koropsak M; Quaresmini G; Allan JN; Furman RR; Bhavsar EB; Pagel JM; Hernandez-Rivas JA; Patel K; Motta M; Bailey N; Miras F; Lamanna N; Alonso R; Osorio-Prendes S; Vitale C; Kamdar M; Baltasar P; Österborg A; Hanson L; Baile M; et alii...

Retrospective Real-Life Comparison of Obinutuzumab Plus Chlorambucil Versus Ibrutinib in Previously Untreated and Unfit Patients with Chronic Lymphocytic Leukemia without TP53 Disruptions. Interim Results from the Italian CLL Campus in Blood

2020
ASL Asti
AOU Città della Salute di Torino

Visentin A; Mauro FR; Pietrasanta D; Fresa A; Vitale C; Ciolli S; Cassin R; Cibien F; Sportoletti P; Gentile M; Rigolin GM; Quaglia FM; Murru R; Gozzetti A; Molica S; Marchetti M; Scarfo L; Reda G; Coscia M; Laurenti L; Pizzolo G; Semenzato G; Foà R; Cuneo A; Trentin L;

Clinical characteristics and outcome of west nile virus infection in patients with lymphoproliferative diseases: A multicenter study in Haematologica

2019
ASL Asti

Visentin A; Nasillo V; Marchetti M; Ferrarini I; Paolini R; Sancetta R; Rigolin GM; Cibien F; Imbergamo S; Riva M; Briani C; Marinello S; Piazza F; Gherlinzoni F; Krampera M; Bassan R; Cuneo A; Marasca R; Semenzato G; Trentin L;

Efficacy and safety of front-line treatment with ibrutinib and rituximab in unfit patients with chronic lymphocytic leukemia (CLL). First report of the GIMEMA LLC1114 study in Haematologica

2019
ASL Asti
AO Ordine Mauriziano

Mauro FR; Molica S; Paoloni F; Reda G; Trentin L; Marchetti M; Pietrasanta D; Coscia M; Marasca R; Sportoletti P; Gaidano G; Orsucci L; Stelitano C; Di Renzo N; Liberati M; Gottardi D; Re F; Ilariucci F; Zinzani PL; Mannina D; Gozzetti A; Molinari AL; Gentile M; Chiarenza A; Laurenti L; Varettoni M; Ibatici A; Murru R; Tani M; et alii...

Ibrutinib and rituximab as front-line treatment for unfit patients with chronic lymphocytic leukemia (CLL). preliminary results from the Gimema LLC1114 study in HemaSphere

2019
AO Ordine Mauriziano
ASL Asti

Mauro FR; Molica S; Paoloni F; Reda G; Trentin L; Marchetti M; Pietrasanta D; Coscia M; Marasca R; Sportoletti P; Gaidano G; Orsucci L; Stelitano C; Di Renzo N; Liberati AM; Gottardi D; Re F; Ilariucci F; Zinzani P; Mannina D; Gozzetti A; Molinari AL; Gentile M; Consoli U; Laurenti L; Arcaini L; Ibatici A; Murru R; Tani M; et alii...

Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. in Haematologica / Haematologica. 2018 Jul;103(7):1209-1217. doi: 10.3324/haematol.2018.189837. Epub 2018 Apr 19.

2018
ASL Asti
AOU Città della Salute di Torino
ASL Vercelli

Eyre TA; Kennedy B; Schuh A; Smolej L; Montillo M; Cortelezzi A; Ciolli S; Forconi F; Gonzalez M; Re F; Gaidano G; Molica S; Marchetti M; Ilariucci F; Meneghini V; Chiarenza A; Marasca R; Amendola A; Billio A; Visco C; Mauro FR; Galieni P; Orlandi EM; Farina L; Delgado AR; Musuraca G; Laurenti L; Coscia M; Perez AM; et alii...

Pretreatment health-related quality of life profile according to the eortc QLQ-C30 in patients with myelodysplastic syndromes (MDS): Analysis on 443 lower-risk MDS patients in Blood

2018
ASL Asti

Efficace F; Ricco A; Breccia M; Frairia C; Fianchi L; Sanpaolo G; Crugnola M; Invernizzi R; Luppi M; Stauder R; Petranovic D; Platzbecker U; Caocci G; Fedele M; Palumbo GA; Cottone F; Patriarca A; Niscola P; Karakantza M; Vignetti M; Canicattì M; Zhang H; Di Renzo N; Cuneo A; Kyriakou C; Voso MT; Fozza C; Santini V; Caers J; et alii...

Efficacy and safety of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia: Results of the GIMEMA-ERIC LLC1315 study in Blood

2017
ASL Asti

Ghia P; Foa R; Follows GA; De La Serna J; Vignetti M; Gaidano G; Ilariucci F; Meneghini V; Chiarenza A; González M; Re F; Marchetti M; Marasca R; Pizzuti M; Visco C; Ciolli S; Orlandi EM; Rivas-Delgado A; Farina L; Musuraca G; Coscia M; Perez AM; Trentin L; Gentile M; Montillo M; Molica S; Mauro FR; Laurenti L; Galieni P; et alii...

Is idelalisib cost-effective for refractory/relapsed chronic lymphocytic leukemia? A decision analysis in the second-line setting in Blood

2015
ASL Asti

Marchetti M; Cuneo A; Mauro FR; Montillo M; Martelli E; Pedone MP;

Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group. in Leukemia research / Leuk Res. 2014 Nov;38(11):1269-77. doi: 10.1016/j.leukres.2014.06.017. Epub 2014 Jul 7.

2014
ASL Asti

Cuneo A; Marchetti M; Barosi G; Billio A; Brugiatelli M; Ciolli S; Laurenti L; Mauro FR; Molica S; Montillo M; Zinzani P; Tura S;